文献速递乳腺癌

绝经前乳腺癌患者辅助戈舍瑞林与他莫昔芬的二十年获益:一项对照随机临床试验

Twenty-Year Benefit From Adjuvant Goserelin and Tamoxifen in Premenopausal Patients With Breast Cancer in a Controlled Randomized Clinical Trial.
PubMed 文献 · J Clin Oncol · 2022-07-21

该研究对 Stockholm 试验(STO-5,1990-1997)中 924 例绝经前乳腺癌患者进行二次分析,随机分配至 2 年戈舍瑞林、他莫昔芬、两者联合或无辅助内分泌治疗,随访 20 年。在雌激素受体阳性患者中,三种内分泌治疗均显著改善远期无远处复发间期,联合治疗未优于单药;基因组低风险患者从他莫昔芬显著获益,高风险患者从戈舍瑞林显著获益。

要点

  • 在 ER 阳性绝经前患者中,戈舍瑞林、他莫昔芬及联合治疗均显著改善 20 年无远处复发间期。
  • 基因组低风险患者显著从他莫昔芬获益,基因组高风险患者显著从戈舍瑞林获益。
  • 基因组高风险患者中戈舍瑞林联合他莫昔芬增加风险,联合治疗未优于单药。

核心结论

  • 在雌激素受体阳性绝经前乳腺癌患者中,2 年辅助内分泌治疗显示 20 年获益,并提示基于肿瘤基因组特征的治疗获益存在差异。
  • 戈舍瑞林联合他莫昔芬治疗未优于单药治疗。
  • 长期随访评估治疗获益至关重要。

研究设计与样本

  • Stockholm 试验(STO-5,1990-1997)的二次分析,随机分配 924 例绝经前患者至 2 年戈舍瑞林(3.6 mg 皮下注射,每 28 天一次)、他莫昔芬(40 mg 口服,每日一次)、戈舍瑞林联合他莫昔芬或无辅助内分泌治疗(对照)。
  • 随机分配按淋巴结状态分层;淋巴结阳性患者(n=459)接受标准化疗(环磷酰胺、甲氨蝶呤和氟尿嘧啶)。
  • 2020 年进行原发肿瘤免疫组化(n=731)和基因表达谱分析(n=586),70 基因标签识别基因组低风险和高风险患者。
  • 采用 Kaplan-Meier 分析、多因素 Cox 比例风险回归和多因素时变灵活参数模型评估远期无远处复发间期(DRFI)。
  • 瑞典高质量登记系统允许完整随访 20 年。

主要发现

  • 在雌激素受体阳性患者(n=584,中位年龄 47 岁)中,与对照相比,戈舍瑞林、他莫昔芬及联合治疗显著改善远期无远处复发间期(多因素风险比[HR]分别为 0.49;95%CI 0.32 至 0.75、HR 0.57;95%CI 0.38 至 0.87 和 HR 0.63;95%CI 0.42 至 0.94)。
  • 观察到显著的戈舍瑞林-他莫昔芬交互作用(P=0.016)。
  • 基因组低风险患者(n=305)显著从他莫昔芬获益(HR 0.24;95%CI 0.10 至 0.60),基因组高风险患者(n=158)从戈舍瑞林获益(HR 0.24;95%CI 0.10 至 0.54)。
  • 基因组高风险患者中,戈舍瑞林联合他莫昔芬增加风险(HR 3.36;95%CI 1.39 至 8.07)。
  • 基因组低风险患者可见持续 20 年的他莫昔芬获益,而基因组高风险患者可见早期戈舍瑞林获益。

关键数值与推荐

  • 雌激素受体阳性患者中,戈舍瑞林 vs 对照:多因素 HR 0.49(95%CI 0.32 至 0.75)。
  • 雌激素受体阳性患者中,他莫昔芬 vs 对照:多因素 HR 0.57(95%CI 0.38 至 0.87)。
  • 雌激素受体阳性患者中,联合治疗 vs 对照:多因素 HR 0.63(95%CI 0.42 至 0.94)。
  • 基因组低风险患者中,他莫昔芬 vs 对照:HR 0.24(95%CI 0.10 至 0.60)。
  • 基因组高风险患者中,戈舍瑞林 vs 对照:HR 0.24(95%CI 0.10 至 0.54);基因组高风险患者中,戈舍瑞林联合他莫昔芬 vs 戈舍瑞林:HR 3.36(95%CI 1.39 至 8.07)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To assess the long-term (20-year) endocrine therapy benefit in premenopausal patients with breast cancer. METHODS: Secondary analysis of the Stockholm trial (STO-5, 1990-1997) randomly assigning 924 premenopausal patients to 2 years of goserelin (3.6 mg subcutaneously once every 28 days), tamoxifen (40 mg orally once daily), combined goserelin and tamoxifen, or no adjuvant endocrine therapy (control) is performed. Random assignment was stratified by lymph node status; lymph node-positive patients (n = 459) were allocated to standard chemotherapy (cyclophosphamide, methotrexate, and fluorouracil). Primary tumor immunohistochemistry (n = 731) and gene expression profiling (n = 586) were conducted in 2020. The 70-gene signature identified genomic low-risk and high-risk patients. Kaplan-Meier analysis, multivariable Cox proportional hazard regression, and multivariable time-varying flexible parametric modeling assessed the long-term distant recurrence-free interval (DRFI). Swedish high-quality registries allowed a complete follow-up of 20 years. RESULTS: In estrogen receptor-positive patients (n = 584, median age 47 years), goserelin, tamoxifen, and the combination significantly improved long-term distant recurrence-free interval compared with control (multivariable hazard ratio [HR], 0.49; 95% CI, 0.32 to 0.75, HR, 0.57; 95% CI, 0.38 to 0.87, and HR, 0.63; 95% CI, 0.42 to 0.94, respectively). Significant goserelin-tamoxifen interaction was observed (P = .016). Genomic low-risk patients (n = 305) significantly benefitted from tamoxifen (HR, 0.24; 95% CI, 0.10 to 0.60), and genomic high-risk patients (n = 158) from goserelin (HR, 0.24; 95% CI, 0.10 to 0.54). Increased risk from the addition of tamoxifen to goserelin was seen in genomic high-risk patients (HR, 3.36; 95% CI, 1.39 to 8.07). Moreover, long-lasting 20-year tamoxifen benefit was seen in genomic low-risk patients, whereas genomic high-risk patients had early goserelin benefit. CONCLUSION: This study shows 20-year benefit from 2 years of adjuvant endocrine therapy in estrogen receptor-positive premenopausal patients and suggests differential treatment benefit on the basis of tumor genomic characteristics. Combined goserelin and tamoxifen therapy showed no benefit over single treatment. Long-term follow-up to assess treatment benefit is critical.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Johansson A, Dar H, van 't Veer LJ, et al. Twenty-Year Benefit From Adjuvant Goserelin and Tamoxifen in Premenopausal Patients With Breast Cancer in a Controlled Randomized Clinical Trial. J Clin Oncol. 2022. PMID: 35862873. doi:10.1200/JCO.21.02844

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。